Amgen keeping bone drug to itself

Amgen CEO, Keven Sharer (photo), said yesterday that he does not foresee the company collaborating with anyone else to market its osteoporosis drug, denosumab, which is still in development.

Sharer said he could not see a potential benefit of collaborating with another U.S. company at this time, but others had suspected that Amgen might seek out a partner, since the company has limited expertise in the primary care market--the chief market for the drug. Still, "It is very hard for me to imagine what another company would bring to us," Sharer said.

Amgen will release additional study data next week, including comparison data with potential future rival Fosamax (made by Merck), and those data will likely pave the path for prospective partnership decisions moving forward.

- read the story at the Wall Street Journal
- find out more at CNN Money 

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.